Date: 2017-02-22
Type of information: Collaboration agreement
Compound: fertility research community
Company: 23andMe (US - CA) Celmatix (USA - NY)
Therapeutic area: Women health - Fertility
Type agreement: collaboration
Action mechanism:
Disease:
Details:
- • On February 22, 2017, Celmatix and 23andMe announced the launch of a new fertility research community. The goal of this initiative is to recruit 4,500 women, aged 18-45, who are trying to conceive or who have recently conceived. In addition to collecting genetic data from participants, the study will longitudinally track clinical, environmental, lifestyle, diet-associated, and fertility outcome metrics. This dataset will contribute to Celmatix’s larger research efforts, which are aimed at understanding factors that contribute to lifelong reproductive potential in a diverse population with the aim of identifying new genetic and other markers related to reproductive health.
- Women aged 18-45 who are trying to conceive or who have recently conceived can participate from home by consenting to provide a DNA sample (saliva), answering online surveys (one every two months for 18 months), and agreeing to share their de-identified, individual-level data with researchers. All study participants will receive 23andMe’s Personal Genome Service® at no cost. The study is currently open to U.S. residents only.
- Celmatix is a next-generation women’s health company transforming reproductive health care through genomics and big data. Its products include Fertilome®, a multigene panel test that reveals what a woman’s DNA says about her reproductive health, and Polaris®, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience.
Financial terms:
Latest news:
Is general: Yes
